Evidence map›Paper›PMID 24120473›Full record

ArticleGastroenterology2014

Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.

Qiuyang Zhang, Chunhua Yu, Sui Peng, Hao Xu, Ellen Wright, Xi Zhang, Xiaofang Huo, Edaire Cheng, Thai H Pham, Kiyotaka Asanuma and 8 more

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Article
  3. Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  8. Article
  9. Article
  10. Epithelial Stem Cells: Making, Shaping and Breaking the Niche.Advances in experimental medicine and biology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. [Effect of Apatinib on Invasion and Migration of Lung Cancer Cells
and Its Mechanism].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Qiuyang ZhangCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Chunhua YuCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Sui PengCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Division of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Hao XuDepartment of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Ellen WrightDepartment of Research and Development, VA North Texas Heath Care System, Dallas, Texas.
Xi ZhangCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Xiaofang HuoCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Edaire ChengCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Pediatrics, Children's Medical Center, Dallas, Texas.
Thai H PhamCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Surgery, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Kiyotaka AsanumaCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Kimmo J HatanpaaDepartment of Pathology, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Davood RezaiCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Research and Development, VA North Texas Heath Care System, Dallas, Texas.
David H WangCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Venetia SarodeDepartment of Pathology, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Shelby MeltonCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Pathology, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas.
Robert M GentaCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Pathology, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Miraca Life Sciences, Inc., Irving, Texas.
Stuart J SpechlerCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Rhonda F SouzaCenter for Esophageal Diseases, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Department of Internal Medicine, VA North Texas Health Care System and the University of Texas Southwestern Medical School, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: rhonda.souza@utsouthwestern.edu.
VA North Texas Health Care System · US

Funding

Role of Acid in the Development of Barrett's EsophagusR01DK063621 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI SOUZA, RHONDA F, SPECHLER, STUART JON · 2002 to 2015
$3.4M
ANTECEDANTS SEQUELAE OF CHILDHOOD ONSET DISEASEK12HD068369 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2011 to 2020
$3.0M
Basic and Clinical Studies on the Role of Bile Acids in Barrett's EsophagusR01CA134571 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SOUZA, RHONDA F, SPECHLER, STUART JON · 2009 to 2013
$1.3M
The Role of Periostin and Th2 Cytokines in Eosinophilic Esophagitis FibrogenesisK08DK099383 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI CHENG, EDAIRE · 2013 to 2016
$595k
NCI NIH HHS R01 CA134571NICHD NIH HHS K12 HD068369NIDDK NIH HHS K08 DK099383NIDDK NIH HHS R01 DK063621
6 · The paper itself

Abstract

BACKGROUND &

aimsTumor cells express vascular endothelial growth factor (VEGF), which induces angiogenesis. VEGF also activates VEGF receptors (VEGFRs) on or within tumor cells to promote their proliferation in an autocrine fashion. We studied the mechanisms of autocrine VEGF signaling in Barrett's esophagus cells.

methodsUsing Barrett's epithelial cell lines, we measured VEGF and VEGFR messenger RNA and protein, and studied the effects of VEGF signaling on cell proliferation and VEGF secretion. We studied the effects of inhibiting factors in this pathway on levels of phosphorylated phospholipase Cγ1 (PLCG1), protein kinase C, and extracellular signal-regulated kinases (ERK)1/2. We performed immunohistochemical analysis of phosphorylated VEGFR2 on esophageal adenocarcinoma tissues. We studied effects of sunitinib, a VEGFR2 inhibitor, on proliferation of neoplastic cells and growth of xenograft tumors in mice.

resultsNeoplastic and non-neoplastic Barrett's cells expressed VEGF and VEGFR2 messenger RNA and protein, with higher levels in neoplastic cells. Incubation with recombinant human VEGF significantly increased secretion of VEGF protein and cell number; knockdown of PLCG1 markedly reduced the recombinant human VEGF-stimulated increase in levels of phosphorylated PLCG1 and phosphorylated ERK1/2 in neoplastic cells. Esophageal adenocarcinoma tissues showed immunostaining for phosphorylated VEGFR2. Sunitinib inhibited VEGF signaling in neoplastic cells and reduced weight and volume of xenograft tumors in mice.

conclusionsNeoplastic and non-neoplastic Barrett's epithelial cells have autocrine VEGF signaling. In neoplastic Barrett's cells, VEGF activation of VEGFR2 initiates a PLCG1-protein kinase C-ERK pathway that promotes proliferation and is self-sustaining (by causing more VEGF production). Strategies to reduce autocrine VEGF signaling (eg, with sunitinib) might be used to prevent or treat cancer in patients with Barrett's esophagus.

Indexed as

AdenocarcinomaAnimalsAntineoplastic AgentsAutocrine CommunicationBarrett EsophagusBiomarkersBiomarkers, TumorCell LineCell ProliferationEsophageal NeoplasmsFemaleHumansImmunohistochemistryIndolesMAP Kinase Signaling SystemMiceAntineoplastic AgentsBiomarkersBiomarkers, TumorIndolesPhospholipase C gammaPLCG1 protein, humanProtein Kinase CPyrrolesSunitinibVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanApoptosisBAR-TBrdUbromodeoxyuridineERKEsophageal Cancerextracellular signal-regulated kinasemessenger RNAMouse ModelmRNAnon-neoplastic, telomerase-immortalized Barrett's epithelial cellphospholipase Cphospholipase Cγ1PKCPLCPLCG1protein kinase Crecombinant human vascular endothelial growth factorrhVEGFshort-hairpin RNAshRNAsiRNAsmall interfering RNAvascular endothelial growth factorvascular endothelial growth factor neutralization antibodyvascular endothelial growth factor receptorVascular Endothelial Growth Factor Receptor 2VEGFVEGF-NAVEGFR

Identifiers

PMID24120473
PMCPMC3899829
OpenAlexW2092869288

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.